Multiomic Diagnostics in Youth With Psychosis
ConditionPsychosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age7-17
SponsorRady Pediatric Genomics & Systems Medicine Institute
About this trial
Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with psychotic symptoms or schizophrenia. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of psychosis that may inform new treatment for future patients.
Eligibility criteria
Qualifiers
Child/adolescent admitted to the Rady Children's CAPS with symptoms of first break psychosis
Biological parents of child/adolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed genetically related to a patient participant.
Disqualifiers
Already received any prior whole genome sequencing or exome sequencing.
Unable to approach the family or patient for enrollment.
Unable to obtain informed consent.
They are known to not be genetically related to the child/adolescent patient participant
Trial design
Treatments tested in this trial
- Genetic: Genomic sequencing and molecular diagnostic results, if any.
- Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov